



Cumulative Index

Volume 47

January	MINORITY ORAL HEALTH, pages 1-186
April	NUTRITION AND ORAL HEALTH, pages 187-430
July	INFECTIONS, INFECTIOUS DISEASES AND DENTISTRY, PART I, pages 431-604
October	INFECTIONS, INFECTIOUS DISEASES AND DENTISTRY, PART II, pages 605-774

Note: Page numbers of article titles are in **boldface** type.

A

- Abscess, mandibular, gram-positive staphylococci in, 615
- Acquired immune deficiency syndrome. See AIDS.
- Acyclovir, in herpes zoster, 523
- African American(s), children, prevalence of *Streptococcus mutans* in, 89 in New York City, prevalence of dental caries among, **57-65** male, study of untreated syphilis in, 4-5 maternal transmission of *Streptococcus mutans* in, **87-101** preterm low birth weight and periodontal disease among, **115-125** urban, incidence of orofacial injuries in, 141
- Aging, functional factors of, affecting nutritional status, 358 physiologic factors of, affecting nutritional status, 356-357 psychosocial factors of, affecting nutritional status, 357-358
- AIDS, 467 incidence of, 468 non-Hodgkin's lymphoma in, 541-542 periodontal disease and, 160 reporting of cases of, 467 US surveillance data on, 468
- Airborne transmission, of occupationally acquired infections, 642

- Alcohol, as influence on nutritional status, 358-359
- American Dental Association, role of dentistry in bioterrorism and, 733 statement on water used in dental treatment, 553
- Amino acids, 195-196
- Anabolic steroids, 251
- Anorexia nervosa, diagnostic criteria for, 397 incidence of, 397 physical symptoms of, 398 systemic problems associated with, 390-391
- Anthrax, 736-738 cutaneous, 738 gastrointestinal, 737-738
- Antibiotic efflux pumps, multidrug, 631
- Antibiotic prophylaxis, as benefit to doctor, 675 financial aspects of, 674-675 for immunocompromised patients, 675 for patients at risk for oral metastatic infections, 675 for reduction of bacteremias, 671-673 in immune deficiency, 727 nonvalvular cardiovascular devices and, 675 principles of, 666-668 problems associated with, **665-679** surgical indications for, 666, 667 to prevent bacterial endocarditis, 665

- Antibiotic resistance, 623-639
definition of, 632
dentistry and, 633-635
development of, 634-635
transposable, 628-629
- Antibiotics, beta-lactam, viridans group streptococci and, 626
enzymatic inactivation of, 630
ideal duration of use of, 635
inappropriate use in dentistry, 633-634
macrolide, resistance to, 627
mechanisms of action of, 627-628
microbial resistance to, mechanisms of, 629-633
“new,” 632
“recycling” of, 633
resistance of *Streptococcus viridans* to, 673
- Antifluoridationists, 228-229
- Antiretroviral therapy, highly active, in HIV disease, 472-473, 477, 483
oral side effects of, 473, 474
toxicities associated with, 473-474
- Antitubercular therapy, drug interactions in, 461
- Arthritis, rheumatoid, and periodontitis, 584-585
treatment of, 585
- Atherosclerosis, oral infections and, 575
- B**
- B-cells, 642-643
- Bacille Calmette-Guérin vaccine, 455
- Bacillus anthracis*, 733, 736-737
- Bacteremia(s), incidence of, 668-669
oral cavity and, 668-669
reduction of, antibiotic prophylaxis and, 671-673
viridans group streptococci, 626
- Bacteria, and systemic conditions with susceptibility to infection, 551
as building blocks of biofilms, 546
cariogenic, xerostomia and, 320
cultures, sensitivity pattern of
antibiotic discs and, 617
gram-negative heterotrophic, in water, 546
in dental waterlines, 548-549
entry into patient during dental procedures, 550
potential pathogenicity of, 549
- oral, and diet, 320
pneumonia and, 583-584
- Bacterial challenge, subgingival, host response to, among ethnic/racial group, 110-111
- Bacterial cultures, from maxillofacial infections, media for culture of, 611
processing of, problems associated with, 619
- Barrier techniques, to prevent transmission of tuberculosis, 460-461
- Beta-lactamase enzyme, 630
- Beta-lactamases, 630
- Beverages, fluoride content of, 233
- Binge eating disorder, 400
- Biofilm(s). See also *Bacteria*.
and dental equipment design, 547-548
definition of, 546
nature of, 546-547
quorum sensing and, 547
- Biological agents, 736-740
CDC categories of, 736
- Biological warfare, history of, 734-735
- Biomedical research, recruitment for, access to health care and, 7
confidence in efficacy of treatments and, 8
difficulties in, 4
educational level and, 8
potential unpleasantness of, 7
interventions and, 7
- Biopsies, for diagnosis of Creutzfeldt-Jakob disease, 507, 510-511
- Bioterrorism, dentistry and, 733-744
increasing threat of, 735
responding to, dentistry's role in, 741-743
- Bioweapons, 735
- Bisphosphonates, 220
- Blood, occupational exposures to, prevention of, 684-685
occupational transmission of pathogens in, risk of, 682-684
- Blood count, complete, 268-271, 272
- Blood dyscrasias, 719
- Blood products, Creutzfeldt-Jakob disease and, 502

- Blood tests, for diagnosis of Creutzfeldt-Jakob disease, 506
- Bloodborne infectious disease, healthcare workers with, American College Health Association and, 751
- American Dental Association and, 750
 - Centers for Disease Control and Prevention and, 745-746, 747-748
- disability antidiscrimination laws and, 752-755
- employment discrimination cases against, 753-754
- legal issues for, 745-756
- precautions for, 748
- risk for transmission, 745-746, 748-749
- Society for Healthcare Epidemiology of America, 750-751
- occupationally acquired, 642
- Body mass index/weight-for height ratio, for children, 280-281
- Bone, calcium in, 213-215
 - effects of parathyroid hormone and calcitonin on, 215, 216
 - formation and resorption of, 213-214
 - health of, and periodontal disease, 215
- Bone density, total body, 219
- Bovine spongiform encephalopathy, 493, 495
- Bulimia nervosa, diagnostic criteria for, 399
 - incidence of, 398-399
 - medical consequences of, 399
- C**
- Caffeine, 251
 - and ephedra, 251
- Calcitonin, 213, 214
 - and parathyroid hormone, effects on bone, 215, 216
- Calcium, 247
 - absorption of, 210-212
 - and osteoporosis, 218-219
 - dietary, and periodontal disease, 317
 - domains in vertebrate body, 209
 - duodenal cell and, 211-212
 - excretion of, 217-219
 - foods rich in, 210
 - homeostasis, 212-213
 - in bone, 213-215
 - in luminal fluid, 210-211
 - in mammals, 209
- in plasma, 212-213
- parathyroid hormone and, 213
- in teeth, 215-217
- nutrition and metabolism of, 209-224
- sources of, 247
- transcellular movement of, 211
- Cancer, development of, dietary compounds and, 414
 - incidence of, vegetable and fruit consumption and, 415
- Cancer patient, nutritional status of, 385-386
- Cancrum oris. See *Noma*.
- Candidiasis, oral pseudomembranous, of buccal mucosa, 476
- Capsaicin, 252
- Carbohydrates, 191-193
 - classifications of, 192, 324
 - recommendations for diet, 192
 - sugars, and sweeteners, caries-promoting potential of, 322, 323
- Cardiovascular disease, and periodontitis, 575-577
 - epidemiologic studies in, 576, 578-579, 580, 581
 - treatment of, 577
- atherosclerosis in, 575
- pathogenesis of, 576-577
- risk factors for, 575-576
- Caries. See *Dental caries*.
- dental. See *Dental caries*.
- Cell mediated deficiencies, 713
- Cellular immunity, impaired, pathogens associated with, 711
- Central nervous system, transmissible spongiform encephalopathies and, 500, 502-503
- Charles Drew University of Medical Sciences, 127, 178
- Chemotherapy, in tuberculosis, 457
- Chickenpox, 522
- Child(ren), African American, prevalence of *Streptococcus mutans* in, 89
 - caries in, dairy products and, 325-326
 - disorders in, nutrition-related, 287
 - emotional development of, and foods for, 285-286
 - food choices of, 294-295
 - environmental influences on, 286

- Child(ren) (*continued*)
 food environment and, 296-297
 HIV-infected, oral manifestations in,
 clinical implications of, **159-174**
 nutrient requirements of, 281-284
 obesity in, 289-291
 physical development of, and foods
 for, 284-285
 snacking and drinking by, 295-296
 weight and height assessments in,
 280-281
- Chlorhexidine, treatment using, effect on
 maternal transmission of *Streptococcus*
 mutans, 96-97
- Chronic wasting disease, 495
- Cleft lip/cleft palate, closure of,
 postsurgical feeding and, 309-312
 dental disease in children with, 313
 etiology of, 305-306
 impact on nutritional health and
 oral-motor development,
 305-317
 infants with, breast feeding and,
 312-313
 nutritional requirements of,
 307-312
 oral-motor development in, 306-307
- Coenzyme Q10, 250
- Committee on Diet and Health, 187
- Committee on Dietary Allowances, 187
- Complement deficiencies, pathogens
 associated with, 711, 713, 714
- Condyloma acuminatum, human papilloma
 virus-associated, 477, 482
- Consumption. See *Tuberculosis*.
- Cranial nerve, impaired function of,
 nutritional status and, 268, 270
- Creatine, 251-252
- Creutzfeldt-Jakob disease, acquired,
 498-501
 Kuru, 498
 transmission of, 501-502
 vCJD, 499-501
 as transmissible spongiform
 encephalopathy, 493
 associated with dental treatment,
 503-504, 506, 507-508
 clusters of, 504
 diagnosis of, 505-509
 identification of patients with, 508
 in exposure to bovine spongiform
 encephalopathy, 499
 incidence of, 497
- inherited, 498
 clinical features of, 498
 maxillofacial surgery in, 511
 percutaneous exposure to fluids of
 patients with, 510
 persons at risk of developing, 509-510
 possible causes of, 497-498
 suspected cases of, management of,
 509
 symptoms of, 497
- Cyclosporin, 723
- Cystic fibrosis, susceptibility to infections
 and, 551
- Cytokines, in wound healing, 374-377
- Cytomegalovirus, 540-541
 as clinical marker for AIDS, 525
 infection with, diagnosis of, 525
 in immunosuppressed patients,
 524
 in neonates, 524
 treatment of, 526
 transmission of, 524
- Cytotoxic drugs, neutropenia and, 716
-
- D**
- Dairy products, childhood caries and,
 325-326
- Delta hepatitis, 660
- Dental caries, analysis of, in HIV-infected
 children, 161
 and composition of whole saliva in
 minority populations, **67-85**
 causes of, 159
 diet and, synergy between, 319-321
 early childhood, 287-288
 in eating disorders, 402-403
 nutrition and, **319-336**
 prevalence among African Americans
 in New York City, **57-65**
 study of, clinical implications of,
 63-64
 data analysis in, 60
 discussion of, 62
 methods of, 59-60
 results of, 60-62
 prevention of, dietary factors in,
 325-327
 fluoride in, 225, 227-228
 promotion of, dietary factors in,
 321-325
- Dental disease, in children with clefts, 313
- Dental equipment, design of, biofilms and,
 547-548

- Dental health, diet and, 269–261
of older adults, 360
- Dental office, waterborne infections and, 545
- Dental practitioners, practice points for, 255
- Dental prevention programs, in eating disorders, 405–407
- Dental schools, recruitment of minorities to, 35
- Dental treatment, complications from, in HIV disease, 483–486
risk of bacterial endocarditis due to, 670–671
- Dental waterlines. See *Waterlines, dental*.
- Dentin, hypersensitivity of, in eating disorders, 403
- Dentist(s), ethnicity of population and, 30
illness of, due to exposure to contaminated dental treatment water, 552–553
role in response to bioterrorism, 741–743
transmission of tuberculosis by, 460
visits to, by race/ethnicity, 33–36
- Dentoalveolar surgery, dietary considerations and, 382–384
- Dentures, diet suggestions in use of, 364–365, 366
effect on food choices and general health, 361–362
effect on taste, swallowing, and chewing, 360–361
- Diabetes mellitus, and periodontitis, 585–586
treatment of, 586
dental treatment in, 389–390
- Diet(s), and dental caries, synergy between, 319–321
and dental health, 269–261
and nutrition, evaluation of, 271–275
in pediatric dentistry, 279–303
effects on periodontal health, 349–351
habits, and oral health, 294–297
of older adults, recommendations for, 362–366
oral bacteria and, 320
pediatric, guidelines for, 281–286
recommendations for, for caries prevention, 327–328
to combat obesity, 415–421
- Diet and health guidelines for Americans, 189, 190
- Dietary counseling, for prosthodontic patients, 355–371
in pediatrics, 297–300
- Dietary education, and dietary screening, in dental practice, 328–332
- Dietary factors, in prevention of caries, 325–327
in promotion of caries, 321–325
- Dietary reference intakes, 187–189
- Dietary screening, and dietary education, in dental practice, 328–332
for older adults, 362
- Dietary supplement(s), certification of, 246
definition of, 245–246
medications and, 265
- Disinfection, methods of, 702–703
of patient care items, infections and, 699–700
- DNA oncogenic viruses, 535–541
- Dwarfism, psychosocial, 292
-
- E**
- Eating, disordered, 292–293
subconscious, 296
- Eating disorders, dental prevention programs in, 405–407
oral manifestations of, 400–405
recognition and management of, in dental office, 395–410
systemic problems associated with, 390–391
- Echinacea, 252
- Electroencephalogram, for diagnosis of Creutzfeldt-Jakob disease, 506
- Encephalopathy(ies), bovine spongiform, 493, 495
scrapielike spongiform, 495
transmissible mink, 495
transmissible spongiform, agents, inactivation of, 508
and dentistry, 503–504
animal, 493, 495
Creutzfeldt-Jakob disease as, 493
description of, 493
infection control and dental treatment in, 505, 507–508, 509
infectious agents in, 494–495
orofacial manifestations of, 503
pathogenesis of, 501
prions and, 493–516
treatment of, 503

Endocarditis, bacterial, absolute risk rate for acquiring, 671, 672
antibiotic prophylaxis to prevent, 665
oral micro-organisms and, 669-670
periodontal disease and, 669
prevention of, best case scenario for, 673
risk of, due to dental treatment, 670-671
Streptococcus viridans and, 668, 669

infective, and oral bacteria, 577-583
bacteria causing, 582
conditions predisposing to, 582
dental treatment and, 583
pathogenesis of, 582
treatment of, 582

Endotoxin, 551
results of exposure to, 551-552

Enteral feeding, for surgical patient, 386-388

Environmental factors, and health behavior, 25, 26-28

Enzyme-linked immunosorbent assay, 470

Eosinophils, 642

Epstein-Barr virus, neoplasms associated with, 538-539
oral hairy leukoplakia and, 527
transmission of, 539

Epstein-Barr virus infection, chronic active, 526
malignancies associated with, 526-527
symptoms of, 526

Ergogenic acids, 250-252

Erythema multiforme, recurring, recurrent herpes simplex virus and, 520

Ethambutol, in tuberculosis, 457
side effects of, 462

F

Failure to thrive, protein energy malnutrition and, 288-289

Fat(s), daily requirements of, 194-195
dietary, 193-194
oral health and, 195
polyunsaturated, 194

Fat substitutes, 195

Fluid hydration, for surgical patient, 388-389

Fluoride(s), added to water, 225, 226-229
daily ingestion of, 235-236
dietary supplements, 229-230
in caries prevention, 225, 227-228
role in nutrition, 225-243
sources in diet, 232
therapeutic, 226-232
to treat osteoporosis, 220-221
toxicity, 236-238

Fluoroquinolones, resistance to, viridans group streptococci and, 627

Fluorosis, skeletal and dental, 236-238

Food(s), choices of, for children, 294-295
fluoride content of, 232-233
functional, 411-413
examples of, 412
rationale for, 412-413
labels on, 190

Food environment, children and, 296-297

Food guide pyramid, 189, 191

Food pyramid, for older adults, 363, 366

Forsyth Institute laboratories, 179

Fructose, malabsorption of, 291-292

G

Garlic, 252-253

Gingival disease, in HIV disease, 482, 483

Gingivitis, 337-338

acute necrotizing, incidence of, 560-561
precursor to noma, 559-560, 564-565
necrotizing ulcerative, fusobacteria and spirochetes in, 616

Ginseng, 253

Granulocytopenia, 719, 722

Green tea, 253

Growth, definition of, 202
nutrients and, 202

Growth and development, normal, 279-281

Growth factors, in wound healing, 377-378

Guarana, 253

H

Hairy leukoplakia, 476, 477

Epstein-Barr virus and, 527

- Head and neck, tuberculosis of, 453
- Health, and health behavior, models for studying, 24-26
determinants of, 22-24
promotion of, nutrition for, **411-423**
- Health behavior(s), and health, models for studying, 24-26
and health perceptions, understanding of, **21-39**
environmental factors and, 25, 26-28
predictors of, 25
- Health care facility, transmission of tuberculosis in, risk categories for, 460
- Health care issues, promotion of, minorities in communications professions and, 35-36
- Health care provider(s), and patient-provider issues, 29
bloodborne infectious disease in. See *Bloodborne infectious disease, healthcare workers with.*
future vaccinations for, 660-661
immunizations and, **641-664**
contraindications, precautions, and adverse reactions to, 657-658
immunocompromised, vaccine considerations for, 658-660
immunoprophylaxis for, recommended, 647, 648
professions included as, 646
specific vaccines for, 649-657
- Health insurance, by race/ethnicity, 27-28
- Health perceptions, and health behaviors, understanding of, **21-39**
- Heavy metals, antibiotic resistant genes and, 632
- Hematopoietic cell transplant, 721
posttransplant complications of, 721-722
- Hepatitis, acute, hepatitis A as cause of, 436
causes of, 432
chronic, hepatitis B as cause of, 437
definition of, 431
human viral, advances in diagnosis and management of, **431-447**
chronic, 433-434
diagnosis of, 432-434
blood test for, 432-433
imaging techniques for, 433
liver function tests in, 433
HIV disease and, 475
- pathogenesis of, 434-443
symptoms of, 431
systems affected by, 434
types of, 434
- Hepatitis A, 646, 647-648
- Hepatitis A vaccine, 656-657
- Hepatitis A virus, acute hepatitis due to, 436
Centers for Disease Control and Prevention recommendation on, 435
countries with endemicity for, 435
infection with, management of, 444
pre-exposure prophylaxis and, 435
transmission of, factors increasing risk of, 435
- Hepatitis A virus vaccines, vaccination schedules for, 435, 436
- Hepatitis B vaccine, 646, 654-656, 661
- Hepatitis B virus, as cause of chronic hepatitis, 437
carriers of, 437
exposure to, assessment and emergency management of, 687-688
management of, 691
postexposure prophylaxis and, 686-687, 688-689, 690, 692
reporting of, 686-687
hepatitis C virus, and HIV disease, risk, prevention, and management of, **681-696**
in hepatocellular carcinoma, 540
infection with, treatment of, 444
morbidity and mortality associated with, 645-646
occupational transmission of, risk of, 683
risk groups for, 437
transmission of, 436
- Hepatitis B virus infection, vaccination against, 686
- Hepatitis B virus vaccine, recommended doses of, 438
- Hepatitis C, vaccine for, development of, 660-661
- Hepatitis C virus, chronic, 439
exposure to, assessment and emergency management of, 687-688
management of, 691-693
postexposure prophylaxis and, 686-687, 688-689, 690
reporting of, 686-687
genotypes of, 440

- Hepatitis C virus (*continued*)
hepatitis B virus, and HIV disease,
risk, prevention, and
management of, 681-696
incidence of, 439-440
infection with, management of,
444-445
neoplasms associated with, 540
occupational transmission of, risk of,
683-684
risk groups for, 438, 439
transmission of, 438
- Hepatitis D virus, 441
and hepatitis B virus infection, 441
genotypes of, 441
- Hepatitis Delta virus, 660
- Hepatitis E virus, 441-442
infection with, management of, 445
- Hepatitis F virus, 442
infection with, management of, 445
- Hepatitis G virus, 442-443
infection with, management of, 445
- Hepatocellular carcinoma, viruses in
development of, 540
- Herbal medicines, and surgical patient,
381-382, 383
- Herbal supplements, 252-254
- Herpes labialis, recurrent, 519-520
- Herpes simplex infections, diagnosis of,
cytology smears for, 521
immunomorphologic tests for,
521
serologic tests for, 522
virologic tests for, 520-521
primary, 518-519
recurrent, 519-520
- Herpes simplex virus(es), 540-541
types of, 518
- Herpes zoster, 522-524
acyclovir in, 523
and postherpetic neuralgia, 523-524
in immunocompromised patients, 523
symptoms of, 523
- Herpesvirus 6, human, 527
in immunocompromised patients,
527-528
treatment of, 528
- Herpesvirus 7, human, 528-529
- Herpesvirus-6B, roseola and, 527
- Herpesvirus infections, update on, 517-532
- Herpesvirus type 8, neoplasia associated
with, 539-540
- Herpesviruses, characteristics of,
517-518
- Hispanic population, in United States,
41-43
oral health promotion for,
obstacles to, 43
- Hispanic subgroups, in New York City,
dental health status and treatment
needs of, 41-55
study of, discussion of, 51-53
methods of, 43-44
results of, 44-51
- HIV, in neoplasms, 541-542
- HIV-associated Kaposi's sarcoma, oral
mucosal lesions of, 539
prevalance of, 541
- HIV disease, 467-492
and tuberculosis, 454-455
antiretroviral drug-resistant
transmission of, 474
clinical staging of, 471
course of, and laboratory monitoring
of, 471
dental treatment considerations in,
483-486
dentists in diagnosis of, 470
diagnosis of, 470
exposure to, assessment and
emergency management of,
687-688
management of, 688
postexposure prophylaxis and,
686-687, 688-689, 690
reporting of, 686-687
- hepatitis B virus, and hepatitis C virus,
risk, prevention, and
management of, 681-696
- hepatitis viral infections with, 475
medical management of, 472-475
occupational exposure to, 469
occupational transmission of, risk of,
682-683
- opportunistic disease and, prevention
and treatment of, 474-475
- oral mucosal lesions in, and
periodontal disease, 475-482
- oral opportunistic diseases and,
478-481
- pathogenesis of, 469-470
- reporting of cases of, 467
- salivary gland dysfunction in,
477-482
- suppression of HIV viremia and,
472-475

- testing for, 470
transmission of, 469
by dentists, 746
hepatitis B virus immunization and, 747
prevention of, 747
vaccine for, development of, 661
- HIV-infected children, oral manifestations in, **159-174**
discussion of, 168-172
study of, caries prevalence and incidence of, 164-165
demographics and, 160-161
dental caries analysis and, 161
methods of, 160-163
oral mucosal lesion analysis and, 162, 165-166
periodontal disease analysis in, 162, 166-168
statistical analysis and, 162-163
- Hormone replacement therapy, 220
- Hospital, inner-city public, population served by, 128
profile of, 128
- Host defense, disorders affecting, 710-712
- Human immunodeficiency virus. See *HIV disease*.
- Humoral deficiencies, 713
- Huntsville Study, 12
- I**
- IgA deficiency, 712-714
- IgG levels, *Porphyromonas gingivalis*, and low birth weight, 120, 121
- Illness, human, in exposure to contaminated dental treatment water, 552-553
- Immune defense, functional defects in, 720
- Immune deficiency(ies), acquired, 715-727
antibiotic prophylaxis in, 727
common, 712-714
primary, 712-715
causes of, 712
- Immune response, 710
- Immune senescence, 348
- Immune status, alterations in, persons at risk for, 348
- Immune suppression, and considerations for dental care, **709-731**
- Immune system, 710
and periodontal disease, 341-342
dysfunction of, results of, 710
- Immune system, immunizations and, 641-645
- Immunity, infection, and nutritional status, interaction of, 340-349
malnutrition and, 343
nutritional strategies to enhance, 350-351
- Immunization(s), active, 644
and immune system, 641-645
for health care providers, contraindications, precautions, and adverse reactions to, 657-658
health care providers and, **641-664**
indicated for oral health personnel, 645-646
passive, 644
process of, 643
terms associated with, 644
- Immunocompetent states, immunologic events in, 710
- Immunocompromised host, dental considerations in, 726-727
host integrity and, 723-724
oral health care for, 723
risk of infection in, 724
- Immunocompromised patients, antibiotic prophylaxis for, 675
definition of, 709
management of, dental clinician and, 709
- Immunodeficiency disease, common variable, 714
severe combined, 714
- Immunodeficiency(ies), acquired, 715
causes of, 716
combined, 713
- Immunoglobulin abnormalities, pathogens associated with, 711
- Immunoprophylaxis, recommended, for health care providers, 647, 648
- Immunosuppressive drugs, posttransplant, 722-723
- Infant, nutrition of, transition stage of, 284
with clefts, breast feeding and, 312-313
nutritional requirements of, 307-312

- Infant formulas, fluoride content of, 234-235
- Infection(s), aerosolized, protection against inhalation of, 461
and cleaning, disinfection, and sterilization of patient care items, 699-700
biofilm-mediated, 547
cell-mediated immunity and, 718-719
control of, 697-708
in health care settings, 704
precautions in, 698-699
program development for, 701-705
program evaluation in, 706-707
rationale for, 697-698
Web-based resources for, 706
effect on nutritional status, 346-348
exposure to, prevention of, 699
immunity, and nutritional status, interaction of, 340-349
maxillofacial, bacterial cultures from, media for culture of, 611
mortality due to, 623-624
nutrition, and periodontal disease, 337-354
occupationally acquired, from airborne and bloodborne transmission, 642
opportunistic, in immunocompromised host, 725
oral, 360
and systemic diseases, 575-598
oral metastatic, antibiotic prophylaxis for patients at risk for, 675
prevention of, nutritional strategies for, 350-351
risk of, in immunocompromised host, 724
susceptibility to, in immunocompromised host, 724-725
transplant recipient and, 721
waterborne, dental office and, 545
- Infectious disease, diagnosis of, laboratory methodologies for, 614-615
diagnostic modalities for, 605-621
- Influenza, 646
- Influenza vaccine, 653-654
- Insurance, health, by race/ethnicity, 27-28
- Integrons, 629
- Intraoral and extraoral examination, in nutrition evaluation, 267-268
- Iron deficiency, in children, 293-294
- Isoniazid, in tuberculosis, 457
side effects of, 461, 462
-
- K**
- Kaposi's sarcoma, 528
epidemiologic forms of, 539
HIV-associated, oral mucosal lesions of, 539
prevalence of, 541
malignant tumors induced by, 529
pathogenesis of, 540
sexual transmission of, 529
- Kaposi's sarcoma-associated herpesvirus, neoplasia associated with, 539-540
- Kava, 254
- King/Drew Medical Center, 128
- Koch's postulates, 533
- Kostmann's syndrome, 717
- Kuru, 498
-
- L**
- Labels, food, 190
- Leukoplakia, hairy, 476, 477
Epstein-Barr virus and, 527
- Lip, recurrent herpes simplex infection of, 519-520
- Lipids, dietary, 193-195
- Long-term-care facilities, antibiotic resistant micro-organisms and, 624-625
- Low birth weight, IgG levels, and *Porphyromonas gingivalis*, 120, 121
in preterm infants, and periodontal disease among African Americans, studies of, 116-117
discussion of, 121-123
materials and methods in, 117-119
results of, 119-121
sample size and power in, 118
statistical analyses in, 118-119
and periodontal diseases, among African Americans, 115-125
definition of, 115
predictors of, 120, 121
periodontitis, 586-590
- T-Lymphotropic 1 virus, human, neoplasia and, 541
- Lysine, 246-247

M

Ma Huang, 251

Magnetic resonance imaging, for diagnosis of Creutzfeldt-Jakob disease, 507

Malignant disorders, and myelodysplasia, 719-720

Malnutrition, and immunity, 343

chronic, noma and, 565

enamel hypoplasia associated with, 320

Mandible, abscess of, gram-positive staphylococci in, 615

Masks, to prevent transmission of tuberculosis, 461

Maxillofacial infections, bacterial cultures from, media for culture of, 611

Maxillofacial surgery, in Creutzfeldt-Jakob disease, 511

Measles, 645, 649

mumps, rubella vaccine, 649-651, 660
noma and, 564, 565

Medications, as influence on nutritional status, 358

dietary supplements and, 265

herbal, and surgical patient, 381-382, 383

Meharry Medical College's School of Dentistry, 177, 178

Meningococcal disease, 648

Mercury, dental amalgam, 632

Metabolic response, in response to surgery/injury, 374, 375

Micro-organisms, antibiotic resistant, long-term-care facilities and, 624-625
mechanisms for genetic variation, 628
oral, bacterial endocarditis and, 669-670

Microbial disease, diagnosis and treatment of, 606
etiologies of, 605

Microbial resistance, 624
in oral cavity, 625-627

Microbial specimens, collection and transport of, 606-610
collection of, before antibiotic chemotherapy, 607
blood cultures and, 607
smear of fluid material and, 608
swabs and containers for, 607
transport of, 606-610

commonly submitted, collection and

transport of, 610, 612-613
diagnostic techniques and methods

for, 610-618

Gram-stained patient abscess smears, 609

results and laboratory evaluation of, 618-620
reporting of, 618-620

transport of, for laboratory analysis, 608-609

Microbiologic flora, oral, 338-340

Micronutrients, deficiencies of, and immune response, 343-346

Microorganisms, periodontal disease due to, 339

Milk, fluoridated, 231

Minerals, 203-204

dietary sources of, 200-201
requirements for, 200

Mink encephalopathy, transmissible, 495

Minority populations, composition of whole saliva and caries experience in, 67-85

destructive periodontal diseases and, 103-114

oral health of, regional research centers for, legacy of, 175-181
research in. See *Research Centers, Regional, for Minority Oral Health*.

recruitment of, to dental schools, 35
underserved, orofacial injuries in, 127-139

Monocytes, 642

Mother, transmission of *Streptococcus mutans* by, in African American population, 87-101

Mucositis, oral, pathogens associated with, 711

Mumps, 645, 650-651

Myelodysplasia, malignant disorders and, 719-720

Myobacterium tuberculosis, 449, 450

N

National Center for Bioethics, 11

National Health and Nutrition Examination Survey, 58

Needle devices, with engineered safety features, 685

- Neonates, infection with cytomegalovirus, 524
- Neoplasm(s), associated with Epstein-Barr virus, 538-539
associated with hepatitis C virus, 540
associated with herpesvirus type 8, 539-540
associated with Kaposi's sarcoma-associated herpesvirus, 539-540
epidemiology pattern of, 534
growth of, viruses and, 533-543
HIV in, 541-542
human papillomaviruses and, 535-536
human T-lymphotrophic 1 virus and, 541
pathogenesis of, 534-535
viral etiology of, criteria for establishing, 533
viruses linked to, 534
- Neuralgia, postherpetic, herpes zoster and, 522-524
- Neurohumeral mediators, in response to surgery/injury, 374
- Neutropenia, causes of, 716-717
congenital causes of, 717
definition of, 716
immune-mediated, 717
pathogens associated with, 711
severe congenital, 717
treatment-related, 717
- Neutrophils, 642
- New York University College of Dentistry, 58-59, 179
- Noma, as forgotten disease, 559-573
clinical presentation of, 561-563
description of, 559
diagnosis of, 562-563
etiology and pathogenesis of, 563-567
history of, 559-560
incidence of, 560
initial oral lesions and, 561
lesions of, microbiota of, 565-566
reconstructive surgery in, 568-569
risk factors for acquiring, 564-565
social and cultural aspects of society of source, 567
survivors of, disfigurements in, 563
treatment of, 567-569
trigger organisms of, 566
trismus associated with, 563, 567, 568
- World Health Organization noma network and, 569-570
- Noma neonatorum, 561
- Non-Hodgkin's lymphoma, in AIDS, 541-542
- Northeastern Minority Oral Health Research Center, 180
- Nutrients, 191-202
antioxidant properties of, 205
in oral tissues growth, development, and health, 202-205
- Nutrition, and dental caries, 319-336
and oral health, 187-207
and wound healing, 378-380
definition of, 187
diet and, evaluation of, 271-275
in pediatric dentistry, 279-303
for health promotion, 411-423
for surgical patient, 373-393
gerodontic, for prosthodontic patients, 355-371
infection, and periodontal disease, 337-354
of older adults, optimizing of, 362-366
plaque biofilm and, 339-340
role of fluorides in, 225-243
- Nutrition Labeling and Education Act of 1990, 190
- Nutrition-risk questions, 277-278
- Nutrition-risk screens, 260-262
- Nutritional screening, 259
- Nutritional status, clinical and laboratory assessment of, 259-278
effect of infection on, 346-348
evaluation of, in surgical patient, 380-381
immunity, and infection, interaction of, 340-349
laboratory tests to assess, 268-271
medical history and, 263-265
of older adults, 355-356
patient history and, 262-263
physical assessment of, 265-268
systemic diseases associated with, 263, 269
- Nutritional supplements, 246-250
definition of, 246
ergogenic acids, and herbals, 245-258
uses and concerns for dental practitioner, 248-249
- Nutritional support, for surgical patient, 386-389

O

- Obesity, childhood, 289-291
 dental treatment in, 391-392
 diets to combat, 415-421
- Occupational exposure, to contaminated dental treatment water, 552
- Older adults, dental health of, 360
 nutritional status of, 355-356
 optimizing diet and nutrition in, 362-366
- Oral cavity, bacteremias and, 668-669
 microbial resistance in, 625-627
- Oral fluids, testing for antibodies, in diagnosis of HIV disease, 470
- Oral health, dietary habits and, 294-297
 minority, regional research centers for, 175-181
 nutrition and, 187-207
 status of, determination of, conceptual framework for, 23-24
- Oral health care, for immunocompromised host, 723
- Oral health care setting, diseases with predilection for transmission in, 647
- Oral health service, utilization of, and oral health status, factors affecting, 30, 31-33
- Oral health status, utilization of oral health service and, factors affecting, 30, 31-33
- Oral infections, and systemic diseases, 575-598
- Oral mucosal lesions, analysis of, in HIV-infected children, 162
 HIV-associated, and periodontal disease, 475-482
 of HIV-associated Kaposi's sarcoma, 539
 of tuberculosis, 453-454
- Orofacial injury(ies), in underserved minority populations, 127-139
 and associated risk factors, 132-135
 and recurrent injury, 135-136
 discussion of, 136-137
 nature of injuries and, 131-132
 patient sociodemographics and, 130-131
 socioeconomic impacts of, 132
 spectrum of, 129
 studies of, background of, 128
 methods of, 129-130
 results of, 130-136

- substance use and, 133, 135
- incidence of, in urban African American population, 141
- psychosocial sequelae of, 145-152
 and correlates of, 141-157
 study of, 142-156
 clinical implications observed in, 155-156
 patient characteristics in, 143
 patient compliance and, 153-154
 risk factors for injury and recurrent injury and, 143
 showing psychological distress, 144
 support needs during recovery and, 152-153
- University of California-LA/Drew Regional Research Center for Minority Oral Health Experience investigations, 142-156

- Orthognathic surgery, dietary considerations and, 384-385
- Osteoblasts, 214-215
- Osteocytes, 215
- Osteoporosis, calcium and, 219-221
 diet and, 293
 treatment of, 220-221

P

- Papillomaviruses, human, 535-538
 and neoplasia, 535-536
 lesions of, cells of, 537
 malignant potential of, 536
 replication of, 536
- Parathyroid hormone, and calcitonin, effects on bone, 215, 216
 calcium in plasma and, 213
- Parenteral nutrition, total, for surgical patient, 388
- Pathogens, waterborne, and dental waterlines, 545-557
- Patient care items, and environmental surfaces, categories of, 700
 cleaning, disinfection, and sterilization of, infections and, 699-700
- Patient(s), illness of, due to exposure to contaminated dental treatment water, 552-553

- Patient(s) (*continued*)
transmission of tuberculosis to, 460
with tuberculosis, management of, 458-462
- Pediatric dentistry, diet and nutrition in, 279-303
- Pediatrics. See also *Child(ren)*.
dietary counseling in, 297-300
- Penicillin, 623
allergy to, 674
viridans group streptococci resistance to, 673
- Percutaneous injury, risk of, 684
postexposure prophylaxis in, 690
- Periodontal disease(s), AIDS and, 160
analysis of, in HIV-infected children, 162
and HIV-associated oral mucosal lesions, 475-482
bacterial endocarditis and, 669
bone health and, 215
causes of, 159
destructive, clinical and demographic parameters and, according to ethnic/racial group, 107, 108
in minority populations, 103-114
incidence and progression of, 104-109
risk indicators and risks associated with, 109-112
Surgeon General's report on, 103-104
dietary calcium and, 217
immune system and, 341-342
in eating disorders, 404
in HIV disease, 482, 483
microorganisms associated with, 339
nutrition, and infection, 337-354
preterm low birth weight and, among African Americans, 115-125
systemic diseases influencing, 575
vitamin C and, 247-250
- Periodontitis, 337-338
and diabetes mellitus, 585-586
treatment of, 586
- cardiovascular disease and, 575-577
epidemiologic studies in, 576, 578-579, 580, 581
treatment of, 577
- low birth weight and, 586-590
preterm birth and, 586-590
rheumatoid arthritis and, 584-585
treatment of, 585
- Periodontium, effects of dietary intake on, 349-351
- Phagocytic deficiencies, 713
- Phagocytic dysfunction, 718
- Pharyngitis, pharyngeal exudate in, 616
- Phytochemicals, compounds included in, 413
functions of, 413-414
health promoting effects of, 413
- Pica, 292
- Plant foods, as anticariogenic agents, 326-327
- Plaque biofilm, 338-339
host nutrition and, 339-340
- Plasma, calcium in, 212-213
parathyroid hormone and, 213
- Plasmids, 628-629
- Pneumocystic carinii pneumonia, HIV disease and, 474-475
- Pneumonia, and oral bacteria, 583-584
therapeutic consequences of, 584
community-acquired, 583
hospital-acquired, 583-584
- Porphyromonas gingivalis*, IgG levels, and low birth weight, 120, 121
- Posttraumatic stress disorder symptoms, following orofacial injuries, 146, 147, 148, 149, 150, 151
- Pregnancy, effect of, on maternal levels of *Streptococcus mutans*, 95
- Preterm birth, periodontitis and, 586-590
- Preterm infants, low birth weight, and periodontal diseases, among African Americans, 115-125
- Prion diseases. See *Encephalopathy(ies), transmissible spongiform*.
- Prions, and human transmissible spongiform encephalopathies, 493-516
description of, 493, 505
in human trigeminal nerve and oral tissue, 504-505
locations of, detection of, animal studies of, 496
transmission by dental route, animal studies of, 496
- Prosthodontic patients, gerodontic nutrition and dietary counseling for, 355-371
- Protein(s), complete, 196

- dietary, 195-197
inadequate intake of, 196
serum circulating, nutritional status and, 381
- Protein energy malnutrition, and failure to thrive, 288-289
- Provitamin, 199-200
- Psychosocial sequelae, of orofacial injuries, psychosocial sequelae of, and correlates of, 141-157
- Pyrazinamide, in tuberculosis, 457
side effects of, 462
- Pyrogenic reactions, 551
- R**
- Ramsay-Hunt syndrome, 523
- Recommended dietary allowances, 187, 189
- Regional Research Centers for Minority Oral Health. See *Research Centers, Regional, for Minority Oral Health.*
- Research Centers, Regional, for Minority Oral Health, 21, 30, 31, 32, 58, 127, 175, 181
meetings of, 176-177
- Research centers, Regional, for minority oral health, goals of, 176
legacy of, 175-181
- Research issues, 254
- Retroviruses, 541
- Reye's syndrome, 522
- Rheumatoid arthritis, and periodontitis, 584-585
treatment of, 585
- Rifampin, in tuberculosis, 457
side effects of, 461-462
- RNA oncogenic viruses, 541
- Roseola, human herpesvirus-6B and, 527
- Rubella, 645, 651
- Rumination, 292
- S**
- Saliva, as complex secretion, 74-75
function of, 320
functions of, 67
whole, caries prediction and, protocol for, 76
cariogenic organisms in, 68
- collection of, 68
composition of, and caries experience, in minority populations, 67-85
- microbiological assay of, 68-69
results of, 69-74
statistical analyses of, 69
- pathogenic bacteria in, by ethnicity, 71, 72-73
- study(ies) of, discussion of, 74-82
materials and methods for, 68-69
participants in, 68, 70
smoking by participants in, and socioeconomic status, 68, 70
- Salivary glands, dysfunction of, in HIV disease, 477-482
hypertrophy of, in eating disorders, 404
- Salt, fluoridated, 230-231
- Scrapie, 493, 495
- Scrapielike spongiform encephalopathy, 495
- Screening enzyme immunoassay, 470
- Sepsis, 719
- SMA panel, 271-273
- Smallpox, 738-740
course of disease, 739
in United States, 738
spread of, 739
vaccination against, 739-740
contraindications to, 740
- Soft tissue, lesions of, in eating disorders, 405
- Spaulding classification scheme, of patient care items, 699-700
- Splenectomy, pathogens associated with, 711
- Spongiform encephalopathies, transmissible. See *Encephalopathy(ies), transmissible spongiform.*
- Squamous cell carcinoma, human papillomavirus and, 536, 538
- Stature, assessment of, in children, 280
- Sterilization, methods of, 702-703
of patient care items, infections and, 699-700
- Steroids, anabolic, 251
- Stool, calcium excretion in, 218-219

- Streptococcus mutans*, epidemiology of, 88-92
findings from cross-sectional study, 89-90
findings from longitudinal studies, 90-92
maternal levels of, effect of pregnancy on, 95
maternal transmission of, effect of chlorhexidine treatment on, 96-97
effect of delivery on, 95-96
fidelity of, 93-95
in African American population, 87-101
maternal attributes to, 95-97
prevalence of, in African American children, 89
in different ethnic populations, 88-89
transmission of, 92-93
- Streptococcus viridans*, antibiotic resistance of, 673
bacterial endocarditis and, 668, 669
- Streptococcus pneumoniae*, mortality due to, 625
- Streptomycin, in tuberculosis, 457
side effects of, 462
- Sugar(s), accusations against, 192-193
carbohydrates, and sweeteners, caries-promoting potential of, 322, 323
forms of, in processed foods, 193
- Sugar substitutes, caries-promoting potential of, 326
- Supplements. See also *Dietary supplement(s); Nutritional supplements.*
interactions of, 254-255
questions regarding use of, 255
- Surgical patient, evaluation of nutritional status in, 380-381
herbal medicines and, 381-382, 383
nutritional considerations in, 373-393
nutritional support for, 386-389
- Sweeteners, alternative, 193
carbohydrates, and sugars, caries-promoting potential of, 322, 323
caries-promoting potential of, 326
- Syphilis, untreated, in African American male, study of, 4-5
- Systemic diseases, associated with nutritional status, 263, 269
oral infections and, 575-598
- Systemic inflammatory response syndrome, 719
-
- T**
- T-cells, 643
- Taste and smell, as influence on nutritional status, 359-360
- Tea tree oil, 253-254
- Teas, caries prevention and, 327
- Tetanus-diphtheria injections, 645
- Tetanus vaccine, 652-653
- Tetracycline, antibiotic resistant genes and, 632
- Tobacco use, carcinomas associated with, 537-538
- Tooth(Teeth), calcium in, 215-217
development of, nutrition and, 204
erosion of, in eating disorders, 400-402, 403
- Trace minerals, 200
- Transfusion-transmitted virus, 443
- Transmissible spongiform encephalopathies. See *Encephalopathy(ies), transmissible spongiform.*
- Transplant recipient, cellular immunity and, 721
immune status of, 720
infections and, 721
medications taken by, 722
- Trauma surgery, dietary considerations and, 385
- Triglycerides, 194
- Trismus, associated with noma, 563, 567, 568
- Tuberculin, old, 455
- Tuberculin skin testing, 456
- Tuberculosis, 449-465, 647
as global, 449
extrapulmonary, manifestations of, 452
granulomatous inflammation in, 451
history of, 449
HIV disease and, 454-455, 475

incidence of, 449-450
 management of, 455-458
 management of dental patient with,
 458-462
 military, 453
 of head and neck, 453
 oral manifestations of, 453-454
 pulmonary manifestations of, 451
 reactivation of, 451-452
 secondary, 451
 testing for, 456
 transmission of, 450-453
 barrier techniques to prevent,
 460-461
 Centers for Disease Control and,
 458
 dental workers and, 459-460
 dentist-to-patient, 460
 in health care facility, risk
 categories for, 460
 treatment of, 456-458
 vaccination in, 455

Tuberculosis vaccine, 657

Tuskegee Legacy Project, 1-19, 180
 3 City study, 13-14
 4 City study, 14-15
 and additional pilot summer studies,
 12-13
 legacy of, 15
 origins of, 1-3
 proposed, significance of, 8-9
 questionnaire, development at
 workshop, 10-11
 summer pilot studies to develop,
 9-10
 unanticipated societal benefits of,
 11-12

Tuskegee syphilis study, background of, 3-8

U

Ubiquinone, 250

United States Food and Drug
 Administration (FDA), 705

University of California in Los Angeles, 127

University of California-LA/Drew Regional
 Research Center for Minority Oral
 Health Experience, investigations of
 orofacial injuries, 142-156

Urine, calcium excretion in, 217-218

V

Vaccination, against hepatitis B virus
 infection, 686

in tuberculosis, 455
 origin of term, 643

Vaccine(s), composition of, 644
 for immunocompromised health care
 providers, 658-660
 synthetic, 645
 tuberculosis, 657

Valerian, 254

Vancomycin-resistant enterococci, 624

Varicella, 522

Varicella vaccine, 645, 651-652

Varicella zoster virus, 522-524

Verrucous carcinoma, human
 papillomavirus and, 537-538

Viridans group streptococci, bacteremias,
 626
 beta-lactam antibiotics and, 626

Virus(es), and neoplastic growth,
 533-543
 classification of, 533-534

DNA oncogenic, 535-541

RNA oncogenic, 541

Vitamin A, importance of, 205

Vitamin C, deficiency of, effects of, 205
 periodontal disease and,
 247-250

Vitamins, bioavailability of, 199
 classification of, 200, 201-202
 in foods, forms of, 199-200

Vomiting, chronic, oral symptoms of, 401

W

Water, as essential nutrient, 197

bottled, purity of, 199
 sources of, 199
 clean, treatments to produce,
 198-199

daily requirements of, 197, 199

dietary sources of, 197

drinking, sources of, 198

fluorination of, 226-227
 effectiveness in caries prevention,
 227-228
 opposition to, 228-229

Water bacteria, gram-negative
 heterotrophic, 546

Water systems, dental unit, contamination
 of, 548-553

 methods to control, 553
 sources of biofilm in, 548

- Waterlines, dental, and health, 548-553
 biofilms in, 547-548
 diseases caused by, 550
 portals of entry of, 550
 design of, biofilms and, 547-548
 organisms in, potential
 pathogenicity of, 549
 waterborne pathogens and,
545-557
- Weight, assessment of, in children, 280
- Weight-for-height ratio/body mass index,
 for children, 280-281
- World Health Organization noma network,
 noma and, 569-570

- Wound healing, 374-378
 nutrition and, 378-380

X

- Xerostomia, cariogenic bacteria and, 320
 causes of, and dental problems caused
 by, 359
 due to chemotherapy, 386
 in eating disorders, 403

Y

- Yohimbe, 253

